Cardiovasc Drugs Ther (2017) 31:229–232 DOI 10.1007/s10557-017-6741-2 EDITORIAL Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line Editorial to: BEmpagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes^ by N. Hammoudi et al. 1 1 1 Manisha Gupte & Prachi Umbarkar & Hind Lal Published online: 21 July 2017 Springer Science+Business Media, LLC 2017 Type 2 diabetes mellitus (T2DM), which affects 29 million T2DM patients receiving empagliflozin showed significantly Americans, is a major risk factor for the development of car- reduced cardiovascular associated events. While the available diovascular diseases (CVD) such as myocardial infarction and data provide a strong evidence of empagliflozin benefits in heart failure (HF). In the last decade, empagliflozin, a sodium reducing cardiac mortality and morbidity, the mechanism through which empagliflozin exerts its cardiac benefits is un- glucose co-transporter 2 (SGLT-2) inhibitor, has emerged as a novel and promising drug for T2DM patients with benefits known. Therefore, an important challenge remaining is to elu- extending beyond its glucose-lowering action . These com- cidate the molecular mechanism of empagliflozin-mediated prise weight loss, blood pressure reduction, lessening arterial cardiac benefits. stiffness, and a remarkable drop in cardiovascular death [2–5]. The study by
Cardiovascular Drugs and Therapy – Springer Journals
Published: Jul 21, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera